SCHEMBL2744258

SCHEMBL2744258

COC(=O)COc1c(OC)cc(C=O)cc1OC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 13/20 0.59
MAPK1 P28482 1/20 0.59
CYP1A2 P05177 1/20 0.52
CYP2C19 P33261 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.50
APP P05067 1/20 0.47
POLB P06746 1/20 0.47
LMNA P02545 1/20 0.45
FDPS P14324 1/20 0.45
MAPT P10636 2/20 0.45
KDM4E B2RXH2 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
GAA P10253 1/20 0.44
TRIM24 O15164 1/20 0.44
HPGD P15428 1/20 0.44
ALDH5A1 P51649 1/20 0.44
ABAT P80404 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17538707 0.88 ALDH1A1 (0.67) ALDH1A1MAPK1CYP1A2CYP2C19SMN1; SMN2
SCHEMBL2743926 0.85 ALDH1A1 (0.61) ALDH1A1MAPK1CYP1A2CYP2C19SMN1; SMN2
SCHEMBL532027 0.85 ALDH1A1 (0.49) ALDH1A1MAPK1CYP1A2CYP2C19SMN1; SMN2
SCHEMBL15332644 0.84 ALDH1A1 (0.70) ALDH1A1MAPK1CYP1A2CYP2C19SMN1; SMN2
SCHEMBL2557321 0.84 ALDH1A1 (0.81) ALDH1A1MAPK1CYP1A2CYP2C19SMN1; SMN2
SCHEMBL7683038 0.82 SRC (0.47) ALDH1A1MAPK1CYP1A2CYP2C19SMN1; SMN2
SCHEMBL4262680 0.82 FDPS (0.57) ALDH1A1CYP1A2APPLMNAFDPS
SCHEMBL2558197 0.82 ALDH1A1 (0.71) ALDH1A1MAPK1CYP1A2CYP2C19SMN1; SMN2
SCHEMBL4262685 0.82 FDPS (0.57) ALDH1A1CYP1A2APPLMNAFDPS
SCHEMBL2284391 0.81 ALDH1A1 (0.74) ALDH1A1CYP1A2CYP2C19SMN1; SMN2APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178727-B2 Bis(arylmethylidene)acetone compound, anti-cancer agent, carcinogenesis-preventive agent, inhibitor of expression of Ki-Ras, ErbB2, c-Myc and Cycline D1, β-catenin-degrading agent, and p53 expression enhancer NATIONAL UNIVERSITY CORPORATION TOHOKU UNIVERSITY (JP) 2012-05-15 US disclosed
US-20100152493-A1 BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER SHIBATA, HIROYUKI (JP) 2010-06-17 US disclosed
US-7202247-B2 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders ATHEROGENICS, INC. (US) 2007-04-10 US disclosed
US-20030232877-A1 1,3-Bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders CRABTREE ACQUISITION CO, LLC 2003-12-18 US disclosed
WO-2003053359-A2 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPYN-1-ONES AND THEIR USE TO TREAT DISORDERS ATHEROGENICS, INC. (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152493-A1 BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER MYC, CCNE2, CCNE1 ALDH1A1 614/4885MAPK1 546/4885CYP1A2 1717/4885
US-20030232877-A1 1,3-Bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders SLC10A1, PKD1, ABCB11 ALDH1A1 111/4885MAPK1 1497/4885CYP1A2 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.